BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32611501)

  • 21. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW; Shi HY; Dai JJ; Chen H; Wu WH; Qiu XB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):294-301. PubMed ID: 32370480
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy.
    Liebregts M; Vriesendorp PA; Steggerda RC; Schinkel AF; Balt JC; Ten Cate FJ; Michels M; Ten Berg JM
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):945-952. PubMed ID: 26946355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: An Echocardiography and Cardiovascular Magnetic Resonance Imaging Study.
    Lu M; Du H; Gao Z; Song L; Cheng H; Zhang Y; Yin G; Chen X; Ling J; Jiang Y; Wang H; Li J; Huang J; He Z; Zhao S
    Circ Cardiovasc Interv; 2016 Mar; 9(3):e002675. PubMed ID: 26884612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: A comparison with medical therapy.
    Li P; Xue Y; Sun J; Chen M; Yu X; Zhao H; Gao Y; Zhang X; Jiang T; He J
    Clin Cardiol; 2021 Oct; 44(10):1409-1415. PubMed ID: 34302367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy--the Baylor experience (1996-2002).
    Fernandes VL; Nagueh SF; Wang W; Roberts R; Spencer WH
    Clin Cardiol; 2005 Mar; 28(3):124-30. PubMed ID: 15813618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation of immediate decrease in ventricular septal strain after alcohol septal ablation for obstructive hypertrophic cardiomyopathy to long-term reduction in left ventricular outflow tract pressure gradient.
    van Ramshorst J; Mollema SA; Delgado V; van der Wall EE; Schalij MJ; Atsma DE; Bax JJ
    Am J Cardiol; 2009 Jun; 103(11):1592-7. PubMed ID: 19463521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients.
    Yao L; Li L; Lu XJ; Miao YL; Kang XN; Duan FJ
    Cardiovasc Ultrasound; 2016 May; 14(1):18. PubMed ID: 27189485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcohol septal ablation in patients with severe septal hypertrophy.
    Veselka J; Jensen M; Liebregts M; Cooper RM; Januska J; Kashtanov M; Dabrowski M; Hansen PR; Seggewiss H; Hansvenclova E; Bundgaard H; Ten Berg J; Hilton Stables R; Faber L
    Heart; 2020 Mar; 106(6):462-466. PubMed ID: 31471463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring.
    Bleszynski PA; Goldenberg I; Fernandez G; Howell E; Younis A; Chen AY; McNitt S; Bruckel J; Ling F; Cove C; Aktas MK
    Heart Rhythm; 2021 Jan; 18(1):50-56. PubMed ID: 32853778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy.
    Sedehi D; Finocchiaro G; Tibayan Y; Chi J; Pavlovic A; Kim YM; Tibayan FA; Reitz BA; Robbins RC; Woo J; Ha R; Lee DP; Ashley EA
    J Cardiol; 2015 Jul; 66(1):57-62. PubMed ID: 25238885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival after alcohol septal ablation versus conservative therapy in obstructive hypertrophic cardiomyopathy.
    Yang YJ; Fan CM; Yuan JQ; Qiao SB; Hu FH; Guo XY; Li YS
    Cardiol J; 2015; 22(6):657-64. PubMed ID: 26100829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry.
    Nagueh SF; Groves BM; Schwartz L; Smith KM; Wang A; Bach RG; Nielsen C; Leya F; Buergler JM; Rowe SK; Woo A; Maldonado YM; Spencer WH
    J Am Coll Cardiol; 2011 Nov; 58(22):2322-8. PubMed ID: 22093510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of alcohol septal ablation in mildly symptomatic or severely symptomatic patients with hypertrophic obstructive cardiomyopathy].
    Sun JJ; Li PJ; Yu XP; Zhao H; Zhang XL; Tu CC; Zhang MD; Jiang TY; Song XT; He JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 May; 51(5):513-520. PubMed ID: 37198123
    [No Abstract]   [Full Text] [Related]  

  • 36. The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Klopotowski M; Chojnowska L; Malek LA; Maczynska R; Kukula K; Demkow M; Witkowski A; Dabrowski M; Karcz M; Baranowski R; Kusmierczyk-Droszcz B; Kruk M; Jamiolkowski J; Kusmierczyk M; Szumowski L; Ruzyllo W
    Clin Res Cardiol; 2010 May; 99(5):285-92. PubMed ID: 20148331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy.
    Cavigli L; Fumagalli C; Maurizi N; Rossi A; Arretini A; Targetti M; Passantino S; Girolami F; Tomberli B; Baldini K; Tomberli A; Antoniucci D; Yacoub MH; Marchionni N; Stefano PL; Cecchi F; Olivotto I
    Int J Cardiol; 2018 Dec; 273():155-161. PubMed ID: 30213605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation.
    Kwon DH; Kapadia SR; Tuzcu EM; Halley CM; Gorodeski EZ; Curtin RJ; Thamilarasan M; Smedira NG; Lytle BW; Lever HM; Desai MY
    JACC Cardiovasc Interv; 2008 Aug; 1(4):432-8. PubMed ID: 19463341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.
    Sathyamurthy I; Nayak R; Oomman A; Subramanyan K; Kalarical MS; Mao R; Ramachandran P
    Indian Heart J; 2014; 66(1):57-63. PubMed ID: 24581097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy.
    Matsuda J; Kitamura M; Takayama M; Imori Y; Shibuya J; Kubota Y; Sangen H; Nakamura S; Takano H; Asai K; Shimizu W
    Heart Vessels; 2018 Mar; 33(3):246-254. PubMed ID: 28965135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.